Study to Assess the Efficacy and Safety of AZD5718 in Moderate-to-Severe Uncontrolled Asthma
Status:
Recruiting
Trial end date:
2024-02-09
Target enrollment:
Participant gender:
Summary
This is a randomised, placebo-controlled, double-blind study with an active comparator
(montelukast) arm to assess the efficacy and safety of AZD5718 administered at multiple dose
levels over a 12-week treatment period to adult participants with moderate-to-severe
uncontrolled asthma.